 |
|
|
|
Rilmenidine
API |
|
|
|
Haorui supplies high quality Rilmenidine API produced by our
GMP facility that has been successfully inspected by the
FDA.
We offer
competitive prices and support our products with reliable technical and
regulatory services. Rilmenidine API is available from R&D to
commercial quantities. Please contact us for more details. |
| |
|
The following
information is provided for general information purposes
ONLY. |
| |
|
Rilmenidine Description |
|
Rilmenidine
is a prescription medication administered to treat
hypertension. |
|
Rilmenidine
Mode of action |
|
Rilmenidine, an
oxazoline compound with antihypertensive properties, acts on
both medullary and peripheral vasomotor structures.
Rilmenidine shows greater selectivity for
imidazoline receptors
than for cerebral
alpha2-adrenergic receptors,
distinguishing it from reference
alpha2-agonists. |
|
Rilmenidine
Precautions |
- As with all
antihypertensive agents, regular medical
monitoring is required when rilmenidine is
administered to patients with a recent
history of cardiovascular disease (stroke,
myocardial infarction).- Alcohol
consumption should be avoided during
treatment.
- In patients with renal failure, no
dosage adjustment is necessary if creatinine
clearance is greater than 15 mL/min.
- In the absence of documented
experiments in this area, rilmenidine is not
recommended for prescription to children.
- Pregnancy: as with all new molecules,
administration of rilmenidine should be
avoided in pregnant women, although no
teratogenic or embryotoxic effects have been
observed in animal studies.
- Lactation: rilmenidine is excreted in
breast milk, and its use is therefore not
recommended during lactation.
- Effects on the ability to drive motor
vehicles or operate machinery: double-blind,
placebo-controlled studies have not shown
rilmenidine to have any effect on alertness
at therapeutic doses (1or 2 daily
administrations of 1 mg). If these doses are
exceeded, or if rilmenidine is combined with
other drugs capable of reducing alertness,
vehicle drivers or machine operators should
be warned of the possibility of drowsiness.
|
|
Rilmenidine
Side effects |
- At a
dose of 1 mg given as a single daily
administration during controlled trials, the
incidence of side effects was comparable to
that observed with placebo.
- At a dose of 2 mg per day
of rilmenidine, controlled comparative
studies versus clonidine (0.15 to 0.30
mg/day) or alpha2-methyldopa (500 to 1000
mg/day) demonstrated that the incidence of
side effects was significantly lower with
rilmenidine than with either clonidine or
a-methyldopa.
Side-effects are rare,
non-severe, and transient at therapeutic
doses:
asthenia,
palpitations, insomnia, drowsiness, fatigue
on exercise, epigastric pain, dryness of the
mouth, diarrhea, skin rash; and
exceptionally, cold extremities, postural
hypotension, sexual disorders, anxiety,
depression, pruritus, edema, cramps, nausea,
constipation, hot flushes.
Chemical
Structure
Molecular
Formula
C10H16N2O
|
|
Rilmenidine
Clinical Trials 1 |
|
|
Rilmenidine
Patents 1 |
Rilmenidine
Patents 2 |
|
|
|
|
|
